Travere Therapeutics, Inc. today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Quanterix Corporation , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer ("CFO" ...

New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...

Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE)-- Ligand Pharmaceuticals ...

“I’m attending so that I can be seen and heard,” said AKF Ambassador Ashli Littleton, who lives in Clarksville, Tennessee and is attending the Kidney Action Summit for the first time. “We have to be ...

Researchers report the impact of sparsentan vs irbesartan on proteinuria in patients with focal segmental glomerulosclerosis.

Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from ...

Over the last 7 days, the United States market has risen by 3.2%, contributing to a remarkable 31% increase over the past ...